(MXL) MaxLinear - Overview
Stock: SoC, Transceiver, Modem, RF, Analog
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 74.9% |
| Relative Tail Risk | -6.16% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.36 |
| Alpha | -31.28 |
| Character TTM | |
|---|---|
| Beta | 2.299 |
| Beta Downside | 2.495 |
| Drawdowns 3y | |
|---|---|
| Max DD | 75.58% |
| CAGR/Max DD | -0.27 |
Description: MXL MaxLinear January 15, 2026
MaxLinear (NASDAQ:MXL) designs and sells communications system-on-chip (SoC) solutions that combine RF front-ends, high-performance analog, mixed-signal, DSP, security, compression, networking and power-management functions into a single silicon die. The integrated chips are targeted at 4G/5G base-station and backhaul equipment, optical transceivers, Wi-Fi and wired home-router platforms, as well as broadband modems that meet DOCSIS, GPON and VDSL standards.
In fiscal 2023 the company reported revenue of roughly **$560 million**, up **≈12 % YoY**, with a **gross margin of 46 %** and **operating cash flow of $85 million**, reflecting strong demand for 5G infrastructure and broadband access upgrades. R&D intensity remains high at **≈15 % of revenue**, underscoring MaxLinear’s focus on maintaining a differentiated IP portfolio in a rapidly evolving semiconductor landscape.
Key macro drivers include the global rollout of 5G networks-projected to add **$300 billion** in telecom capex through 2027-and the acceleration of fiber-to-the-home deployments, both of which boost demand for high-speed, low-power SoCs. Conversely, the sector faces supply-chain tightness and cyclical inventory adjustments that can pressure short-term order flows.
MaxLinear reaches customers through a mix of direct sales, third-party representatives and a worldwide distributor network, serving OEMs, ODMs and module manufacturers across North America, Asia and Europe.
For a deeper quantitative comparison of MaxLinear’s valuation metrics, you might explore the analysis tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -136.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 8.15 > 1.0 |
| NWC/Revenue: 13.43% < 20% (prev 39.15%; Δ -25.72% < -1%) |
| CFO/TA 0.02 > 3% & CFO 19.6m > Net Income -136.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (87.2m) vs 12m ago 3.26% < -2% |
| Gross Margin: 56.51% > 18% (prev 0.53%; Δ 5598 % > 0.5%) |
| Asset Turnover: 56.23% > 50% (prev 41.59%; Δ 14.64% > 0%) |
| Interest Coverage Ratio: -13.01 > 6 (EBITDA TTM -90.6m / Interest Expense TTM 10.1m) |
Altman Z'' -4.28
| A: 0.08 (Total Current Assets 248.8m - Total Current Liabilities 186.0m) / Total Assets 796.4m |
| B: -0.63 (Retained Earnings -500.4m / Total Assets 796.4m) |
| C: -0.16 (EBIT TTM -130.8m / Avg Total Assets 831.6m) |
| D: -1.61 (Book Value of Equity -499.4m / Total Liabilities 309.6m) |
| Altman-Z'' Score: -4.28 = D |
Beneish M -3.47
| DSRI: 0.42 (Receivables 46.1m/85.5m, Revenue 467.6m/360.5m) |
| GMI: 0.94 (GM 56.51% / 53.37%) |
| AQI: 1.13 (AQ_t 0.61 / AQ_t-1 0.54) |
| SGI: 1.30 (Revenue 467.6m / 360.5m) |
| TATA: -0.20 (NI -136.7m - CFO 19.6m) / TA 796.4m) |
| Beneish M-Score: -3.47 (Cap -4..+1) = AA |
What is the price of MXL shares?
Over the past week, the price has changed by +6.12%, over one month by +0.81%, over three months by +23.65% and over the past year by +12.91%.
Is MXL a buy, sell or hold?
- StrongBuy: 4
- Buy: 0
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MXL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21.6 | 15.1% |
| Analysts Target Price | 21.6 | 15.1% |
| ValueRay Target Price | 18 | -3.7% |
MXL Fundamental Data Overview February 09, 2026
P/S = 3.4976
P/B = 3.5813
P/EG = 0.3937
Revenue TTM = 467.6m USD
EBIT TTM = -130.8m USD
EBITDA TTM = -90.6m USD
Long Term Debt = 123.6m USD (from longTermDebt, last quarter)
Short Term Debt = 18.2m USD (from shortTermDebt, last quarter)
Debt = 145.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 63.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.71b USD (1.64b + Debt 145.0m - CCE 72.8m)
Interest Coverage Ratio = -13.01 (Ebit TTM -130.8m / Interest Expense TTM 10.1m)
EV/FCF = 243.2x (Enterprise Value 1.71b / FCF TTM 7.02m)
FCF Yield = 0.41% (FCF TTM 7.02m / Enterprise Value 1.71b)
FCF Margin = 1.50% (FCF TTM 7.02m / Revenue TTM 467.6m)
Net Margin = -29.23% (Net Income TTM -136.7m / Revenue TTM 467.6m)
Gross Margin = 56.51% ((Revenue TTM 467.6m - Cost of Revenue TTM 203.4m) / Revenue TTM)
Gross Margin QoQ = 57.58% (prev 56.58%)
Tobins Q-Ratio = 2.14 (Enterprise Value 1.71b / Total Assets 796.4m)
Interest Expense / Debt = 1.65% (Interest Expense 2.39m / Debt 145.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -103.4m (EBIT -130.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.34 (Total Current Assets 248.8m / Total Current Liabilities 186.0m)
Debt / Equity = 0.32 (Debt 145.0m / totalStockholderEquity, last quarter 451.9m)
Debt / EBITDA = -0.70 (negative EBITDA) (Net Debt 63.1m / EBITDA -90.6m)
Debt / FCF = 8.99 (Net Debt 63.1m / FCF TTM 7.02m)
Total Stockholder Equity = 474.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -16.44% (Net Income -136.7m / Total Assets 796.4m)
RoE = -28.80% (Net Income TTM -136.7m / Total Stockholder Equity 474.5m)
RoCE = -21.87% (EBIT -130.8m / Capital Employed (Equity 474.5m + L.T.Debt 123.6m))
RoIC = -17.29% (negative operating profit) (NOPAT -103.4m / Invested Capital 597.9m)
WACC = 13.32% (E(1.64b)/V(1.78b) * Re(14.39%) + D(145.0m)/V(1.78b) * Rd(1.65%) * (1-Tc(0.21)))
Discount Rate = 14.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.35%
[DCF Debug] Terminal Value 50.44% ; FCFF base≈7.02m ; Y1≈4.61m ; Y5≈2.10m
Fair Price DCF = N/A (negative equity: EV 22.0m - Net Debt 63.1m = -41.1m; debt exceeds intrinsic value)
EPS Correlation: -75.08 | EPS CAGR: -35.78% | SUE: 0.32 | # QB: 0
Revenue Correlation: -78.73 | Revenue CAGR: -16.13% | SUE: 0.47 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.18 | Chg30d=+0.033 | Revisions Net=+8 | Analysts=11
EPS current Year (2026-12-31): EPS=0.86 | Chg30d=+0.111 | Revisions Net=+9 | Growth EPS=+177.3% | Growth Revenue=+20.9%
EPS next Year (2027-12-31): EPS=1.14 | Chg30d=+0.083 | Revisions Net=+6 | Growth EPS=+32.1% | Growth Revenue=+10.7%